Title:
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. NSABP B47
Protocol Number:
SUBENSABPB47
Phase:
Phase III
Physician:
Carolyn Hendricks
Purpose:
NULL
Eligibility:
NULL
Treatment:
NULL
Population:
Adult
Last Update
05/24/2013 04:02 AM
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts